Lentigen Corporation is a privately held company, incorporated in Delaware in 2004. The company believes it offers a unique and high-potential investment opportunity because Lentiviral Vector technology will be key for the development of genetic and biopharmaceutical products.

Lentigen is positioning itself as the leading manufacturer and producer of Lentiviral Vectors for research, biotechnology and medicine. Lentigen's management is committed to strategic growth that will maximize the value of the company now and into the future. The company intends to attract additional funds from the capital markets in the future and is open to discussing investment opportunities.

For more information, please contact Lentigen at 443.543.5300 or send us a message.